{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:01:28Z","timestamp":1777294888951,"version":"3.51.4"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40272-026-00739-4","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:24:49Z","timestamp":1770488689000},"page":"249-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Myocarditis: Challenges in Diagnosis and Treatment"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8785","authenticated-orcid":false,"given":"Bibhuti B.","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"13","key":"739_CR1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jama.2023.3371","volume":"329","author":"E Ammirati","year":"2023","unstructured":"Ammirati E, Moslehi JJ. Diagnosis and treatment of acute myocarditis. JAMA. 2023;329(13):1098\u2013113.","journal-title":"JAMA"},{"issue":"6","key":"739_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jchf.2024.02.012","volume":"12","author":"E Monda","year":"2024","unstructured":"Monda E, Bakalakos A, Cannie D, et al. Prevalence of pathogenic variants in cardiomyopathy-associated genes in acute myocarditis. JACC Heart Fail. 2024;12(6):1101\u201311.","journal-title":"JACC Heart Fail."},{"issue":"33","key":"739_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"ALP Caforio","year":"2013","unstructured":"Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636\u201348.","journal-title":"Eur Heart J"},{"issue":"6","key":"739_CR4","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000001001","volume":"144","author":"YM Law","year":"2021","unstructured":"Law YM, Lal AK, Chen S, et al. Diagnosis and management of myocarditis in children. Circulation. 2021;144(6):e123\u201335.","journal-title":"Circulation"},{"issue":"4","key":"739_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","volume":"85","author":"MH Drazner","year":"2025","unstructured":"Drazner MH, Bozkurt B, Cooper LT, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol. 2025;85(4):391\u2013431.","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"739_CR6","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","volume":"46","author":"J Schulz-Menger","year":"2025","unstructured":"Schulz-Menger J, Collini V, Gr\u00f6schel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46(40):3952\u20134041.","journal-title":"Eur Heart J"},{"issue":"3","key":"739_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169\u201393.","journal-title":"Nat Rev Cardiol"},{"key":"739_CR8","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2025.3231","author":"MJ Tom\u00e1s","year":"2025","unstructured":"Tom\u00e1s MJ, Pinho AI, Sousa Pinto B, et al. The role of genetics in the prognosis of acute myocarditis: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2025. https:\/\/doi.org\/10.4081\/monaldi.2025.3231.","journal-title":"Monaldi Arch Chest Dis"},{"issue":"11","key":"739_CR9","doi-asserted-by":"publisher","first-page":"e005306","DOI":"10.1161\/JAHA.116.005306","volume":"6","author":"A Arola","year":"2017","unstructured":"Arola A, Pikkarainen E, Sipil\u00e4 JO, et al. Occurrence and features of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc. 2017;6(11):e005306.","journal-title":"J Am Heart Assoc"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.forsciint.2016.12.037","volume":"272","author":"L Li","year":"2017","unstructured":"Li L, Zhang Y, Burke A, et al. Demographic, clinical and pathological features of sudden deaths due to myocarditis: results from a state-wide population-based autopsy study. Forensic Sci Int. 2017;272:81\u20136.","journal-title":"Forensic Sci Int"},{"issue":"4","key":"739_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/jcm10040603","volume":"10","author":"A Golpour","year":"2021","unstructured":"Golpour A, Patriki D, Hanson PJ, et al. Epidemiological impact of myocarditis. J Clin Med. 2021;10(4):603.","journal-title":"J Clin Med"},{"issue":"11","key":"739_CR12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4070\/kcj.2020.0108","volume":"50","author":"J Kim","year":"2020","unstructured":"Kim J, Cho M-J. Acute myocarditis in children: a 10-year nationwide study (2007\u20132016) based on the Health Insurance Review and Assessment Service Database in Korea. Korean Circ J. 2020;50(11):1013.","journal-title":"Korean Circ J"},{"issue":"6","key":"739_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00246-017-1638-1","volume":"38","author":"RJ Butts","year":"2017","unstructured":"Butts RJ, Boyle GJ, Deshpande SR, et al. Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-center cohort. Pediatr Cardiol. 2017;38(6):1175\u201382.","journal-title":"Pediatr Cardiol"},{"key":"739_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41935-025-00451-3","author":"N Fnon","year":"2025","unstructured":"Fnon N, Sharif A, Hassan H, et al. Investigating pathological features of myocarditis-related sudden cardiac deaths in Egypt. Egypt J Forensic Sci. 2025. https:\/\/doi.org\/10.1186\/s41935-025-00451-3.","journal-title":"Egypt J Forensic Sci"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"1129348","DOI":"10.3389\/fcvm.2023.1129348","volume":"10","author":"D Fairweather","year":"2023","unstructured":"Fairweather D, Beetler DJ, Musigk N, et al. Sex and gender differences in myocarditis and dilated cardiomyopathy: an update. Front Cardiovasc Med. 2023;10:1129348.","journal-title":"Front Cardiovasc Med."},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jpeds.2021.07.044","volume":"238","author":"BB Das","year":"2021","unstructured":"Das BB, Kohli U, Ramachandran P, et al. Myopericarditis after messenger RNA coronavirus disease 2019 vaccination in adolescents 12 to 18 years of age. J Pediatr. 2021;238:26-32.e1.","journal-title":"J Pediatr"},{"issue":"11","key":"739_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/17425255.2022.2160318","volume":"18","author":"CC De Las","year":"2022","unstructured":"De Las CC, Arrojo-Romero M, Ruan CJ, et al. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review. Expert Opin Drug Metab Toxicol. 2022;18(11):715\u201327.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"739_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2023.09.039","volume":"261","author":"N Vaziri","year":"2023","unstructured":"Vaziri N, Marques D, Greenway SC, et al. The cellular mechanism of antipsychotic-induced myocarditis: a systematic review. Schizophr Res. 2023;261:206\u201315.","journal-title":"Schizophr Res"},{"issue":"6","key":"739_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00246-006-1430-0","volume":"27","author":"KR Chikwava","year":"2006","unstructured":"Chikwava KR, Savell JVH, Boyd TK. Fatal cephalosporin-induced acute hypersensitivity myocarditis. Pediatr Cardiol. 2006;27(6):777\u201380.","journal-title":"Pediatr Cardiol"},{"issue":"12","key":"739_CR20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1097\/INF.0000000000002844","volume":"39","author":"N Dhochak","year":"2020","unstructured":"Dhochak N, Ram Jat K, Sankar J, et al. Hypersensitivity myocarditis due to antitubercular drugs in children. Pediatr Infect Dis J. 2020;39(12):1088\u201391.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"739_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/PAF.0000000000000288","volume":"38","author":"M Ben Khelil","year":"2017","unstructured":"Ben Khelil M, Chkirbene Y, Mlika M, et al. Penicillin-induced fulminant myocarditis: a case report and review of the literature. Am J Forensic Med Pathol. 2017;38(1):29\u201331.","journal-title":"Am J Forensic Med Pathol"},{"issue":"5","key":"739_CR22","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1378\/chest.126.5.1703","volume":"126","author":"M Pieroni","year":"2004","unstructured":"Pieroni M, Cavallaro R, Chimenti C, et al. Clozapine-induced hypersensitivity myocarditis. Chest. 2004;126(5):1703\u20135.","journal-title":"Chest"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"1677984","DOI":"10.3389\/fimmu.2025.1677984","volume":"16","author":"S Feng","year":"2025","unstructured":"Feng S, Zhao B, Sha S, et al. Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment. Front Immunol. 2025;16:1677984.","journal-title":"Front Immunol"},{"issue":"2","key":"739_CR24","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"739_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE, et al. Cardio-oncology and heart failure: a scientific statement from the Heart Failure Society of America. J Cardiac Fail. 2025;31(2):415\u201355.","journal-title":"J Cardiac Fail"},{"issue":"6","key":"739_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/14779072.2023.2219895","volume":"21","author":"A Matsumori","year":"2023","unstructured":"Matsumori A. Myocarditis and autoimmunity. Expert Rev Cardiovasc Ther. 2023;21(6):437\u201351.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"739_CR27","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/ehf2.13163","volume":"8","author":"R Marcolongo","year":"2021","unstructured":"Marcolongo R, Rizzo S, Cerutti A, et al. The multiple faces of autoimmune\/immune-mediated myocarditis in children: a biopsy-proven case series treated with immunosuppressive therapy. ESC Heart Fail. 2021;8(2):1604\u20139.","journal-title":"ESC Heart Fail."},{"issue":"19","key":"739_CR28","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1161\/CIRCULATIONAHA.108.766022","volume":"119","author":"T Yajima","year":"2009","unstructured":"Yajima T, Knowlton KU. Viral myocarditis. Circulation. 2009;119(19):2615\u201324.","journal-title":"Circulation"},{"issue":"23","key":"739_CR29","first-page":"11479","volume":"27","author":"A Popa","year":"2023","unstructured":"Popa A, Lazea C, Agoston-Coldea L. Novel insights on acute myocarditis in pediatric patients. Eur Rev Med Pharmacol Sci. 2023;27(23):11479\u201395.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"739_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4103\/apc.APC_54_17","volume":"10","author":"S Reddy","year":"2017","unstructured":"Reddy S, Eliassen E, Krueger GR, et al. Human herpesvirus 6-induced inflammatory cardiomyopathy in immunocompetent children. Ann Pediatr Cardiol. 2017;10(3):259\u201368.","journal-title":"Ann Pediatr Cardiol"},{"issue":"7","key":"739_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1161\/01.CIR.0000155615.68924.B3","volume":"111","author":"C Tschope","year":"2005","unstructured":"Tschope C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 2005;111(7):879\u201386.","journal-title":"Circulation"},{"issue":"1","key":"739_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pcad.2006.06.001","volume":"49","author":"MD Spotnitz","year":"2006","unstructured":"Spotnitz MD, Lesch M. Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog Cardiovasc Dis. 2006;49(1):42\u201357.","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"739_CR33","first-page":"e207395","volume":"48","author":"BB Das","year":"2021","unstructured":"Das BB, Sexon Tejtel SK, Deshpande S, et al. A review of the cardiac and cardiovascular effects of COVID-19 in adults and children. Tex Heart Inst J. 2021;48(3):e207395.","journal-title":"Tex Heart Inst J"},{"issue":"8","key":"739_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.CIR.99.8.1091","volume":"99","author":"C Kawai","year":"1999","unstructured":"Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death. Circulation. 1999;99(8):1091\u2013100.","journal-title":"Circulation"},{"key":"739_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fimmu.2020.00539","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Han B. Dysregulated CD4+ T cells and microRNAs in myocarditis. Front Immunol. 2020;11:539.","journal-title":"Front Immunol"},{"issue":"2","key":"739_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jleuko\/qiad143","volume":"115","author":"K Liu","year":"2024","unstructured":"Liu K, Han B. Role of immune cells in the pathogenesis of myocarditis. J Leukoc Biol. 2024;115(2):253\u201375.","journal-title":"J Leukoc Biol"},{"issue":"15","key":"739_CR37","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.121.058457","volume":"146","author":"AS Lota","year":"2022","unstructured":"Lota AS, Hazebroek MR, Theotokis P, et al. Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation. 2022;146(15):1123\u201334.","journal-title":"Circulation"},{"key":"739_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003250","author":"F Seidel","year":"2021","unstructured":"Seidel F, Holtgrewe M, Al-Wakeel-Marquard N, et al. Pathogenic variants associated with dilated cardiomyopathy predict outcome in pediatric myocarditis. Circ Genom Precis Med. 2021. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003250.","journal-title":"Circ Genom Precis Med"},{"issue":"7","key":"739_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jacbts.2021.06.001","volume":"6","author":"AR Kontorovich","year":"2021","unstructured":"Kontorovich AR, Patel N, Moscati A, et al. Myopathic cardiac genotypes increase risk for myocarditis. JACC Basic Transl Sci. 2021;6(7):584\u201392.","journal-title":"JACC Basic Transl Sci."},{"issue":"11","key":"739_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/ejhg.2017.128","volume":"25","author":"AA Maan","year":"2017","unstructured":"Maan AA, Eales J, Akbarov A, et al. The Y chromosome: a blueprint for men\u2019s health? Eur J Hum Genet. 2017;25(11):1181\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"Suppl._","key":"739_CR41","doi-asserted-by":"publisher","first-page":"iv23","DOI":"10.1093\/eurheartjsupp\/suaf004","volume":"27","author":"N D\u2019Ettore","year":"2025","unstructured":"D\u2019Ettore N, Eghbalzadeh K, Oezkur M, et al. Diagnosis and management of patients with fulminant myocarditis. Eur Heart J Suppl. 2025;27(Suppl._):iv23-30.","journal-title":"Eur Heart J Suppl."},{"issue":"13","key":"739_CR42","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1161\/CIRCULATIONAHA.105.548156","volume":"112","author":"U K\u00fcHl","year":"2005","unstructured":"K\u00fcHl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965\u201370.","journal-title":"Circulation"},{"issue":"15","key":"739_CR43","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMra0800028","volume":"360","author":"LT Cooper","year":"2009","unstructured":"Cooper LT. Myocarditis. N Engl J Med. 2009;360(15):1526\u201338.","journal-title":"N Engl J Med"},{"issue":"3","key":"739_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00428-019-02615-8","volume":"475","author":"O Leone","year":"2019","unstructured":"Leone O, Pieroni M, Rapezzi C, et al. The spectrum of myocarditis: from pathology to the clinics. Virchows Arch. 2019;475(3):279\u2013301.","journal-title":"Virchows Arch"},{"key":"739_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100118","volume":"4","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Yang Z, Peng Y, et al. Diagnosis and treatment of eosinophilic myocarditis. J Transl Autoimmun. 2021;4:100118.","journal-title":"J Transl Autoimmun."},{"issue":"19","key":"739_CR46","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","volume":"70","author":"M Brambatti","year":"2017","unstructured":"Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70(19):2363\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"739_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ppedcard.2007.08.002","volume":"24","author":"LT Cooper","year":"2007","unstructured":"Cooper LT. Giant cell myocarditis in children. Prog Pediatr Cardiol. 2007;24(1):47\u20139.","journal-title":"Prog Pediatr Cardiol"},{"issue":"4","key":"739_CR48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.healun.2005.11.444","volume":"25","author":"BB Das","year":"2006","unstructured":"Das BB, Recto M, Johnsrude C, et al. Cardiac transplantation for pediatric giant cell myocarditis. J Heart Lung Transplant. 2006;25(4):474\u20138.","journal-title":"J Heart Lung Transplant"},{"key":"739_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219574","author":"I Kasouridis","year":"2017","unstructured":"Kasouridis I, Majo J, MacGowan G, et al. Giant cell myocarditis presenting with acute heart failure. BMJ Case Rep. 2017. https:\/\/doi.org\/10.1136\/bcr-2017-219574.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"739_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.113.001372","volume":"129","author":"CE Canter","year":"2014","unstructured":"Canter CE, Simpson KE. Diagnosis and treatment of myocarditis in children in the current era. Circulation. 2014;129(1):115\u201328.","journal-title":"Circulation"},{"issue":"1","key":"739_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000990","volume":"6","author":"J Berg","year":"2019","unstructured":"Berg J, Lovrinovic M, Baltensperger N, et al. Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up. Open Heart. 2019;6(1):e000990.","journal-title":"Open Heart."},{"issue":"42","key":"739_CR52","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921\u201364.","journal-title":"Eur Heart J"},{"key":"739_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s42452-024-05802-8","author":"X Yu","year":"2025","unstructured":"Yu X. Role and mechanism of heparin in cardiovascular system. Discov Appl Sci. 2025. https:\/\/doi.org\/10.1007\/s42452-024-05802-8.","journal-title":"Discov Appl Sci"},{"issue":"6","key":"739_CR54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jacc.2018.11.035","volume":"73","author":"C Yeung","year":"2019","unstructured":"Yeung C, Baranchuk A. Diagnosis and treatment of Lyme carditis: JACC review topic of the week. J Am Coll Cardiol. 2019;73(6):717\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"739_CR55","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019415","author":"HK Nordenswan","year":"2021","unstructured":"Nordenswan HK, Lehtonen J, Ekstr\u00f6m K, et al. Manifestations and outcome of cardiac sarcoidosis and idiopathic giant cell myocarditis by 25\u2010year nationwide cohorts. J Am Heart Assoc. 2021. https:\/\/doi.org\/10.1161\/JAHA.120.019415.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"739_CR56","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.hrthm.2021.07.038","volume":"18","author":"MJ Shah","year":"2021","unstructured":"Shah MJ, Silka MJ, Silva JNA, et al. 2021 PACES Expert Consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients. Heart Rhythm. 2021;18(11):1888\u2013924.","journal-title":"Heart Rhythm"},{"issue":"7","key":"739_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13548","volume":"23","author":"S Schubert","year":"2019","unstructured":"Schubert S, Opgen-Rhein B, Boehne M, et al. Severe heart failure and the need for mechanical circulatory support and heart transplantation in pediatric patients with myocarditis: results from the prospective multicenter registry \u201cMYKKE.\u201d Pediatr Transplant. 2019;23(7):e13548.","journal-title":"Pediatr Transplant"},{"issue":"6","key":"739_CR58","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","volume":"141","author":"RD Kociol","year":"2020","unstructured":"Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis. Circulation. 2020;141(6):e69\u201392.","journal-title":"Circulation"},{"issue":"2","key":"739_CR59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIR.0000000000001151","volume":"148","author":"C Bogle","year":"2023","unstructured":"Bogle C, Colan SD, Miyamoto SD, et al. Treatment strategies for cardiomyopathy in children: a scientific statement from the American Heart Association. Circulation. 2023;148(2):174\u201395.","journal-title":"Circulation"},{"issue":"15","key":"739_CR60","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077\u201384.","journal-title":"N Engl J Med"},{"issue":"10","key":"739_CR61","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.healun.2025.06.003","volume":"44","author":"C Irving","year":"2025","unstructured":"Irving C, Azeka E, Adorisio R, et al. The International Society for Heart and Lung Transplantation guidelines for the management of pediatric heart failure (update from 2014). J Heart Lung Transplant. 2025;44(10):e21-71.","journal-title":"J Heart Lung Transplant"},{"key":"739_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133521","volume":"438","author":"SAG Lava","year":"2025","unstructured":"Lava SAG. SGLT2 inhibitors for paediatric heart failure: time for innovative trials. Int J Cardiol. 2025;438:133521.","journal-title":"Int J Cardiol"},{"issue":"18","key":"739_CR63","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"36","key":"739_CR64","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"9","key":"739_CR65","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.healun.2014.06.002","volume":"33","author":"R Kirk","year":"2014","unstructured":"Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant. 2014;33(9):888\u2013909.","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"739_CR66","first-page":"1535","volume":"29","author":"PF Kantor","year":"2013","unstructured":"Kantor PF, Lougheed J, Dancea A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol. 2013;29(12):1535\u201352.","journal-title":"Can J Cardiol"},{"issue":"10","key":"739_CR67","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","volume":"70","author":"D Bonnet","year":"2017","unstructured":"Bonnet D, Berger F, Jokinen E, et al. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol. 2017;70(10):1262\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"739_CR68","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","volume":"150","author":"R Shaddy","year":"2024","unstructured":"Shaddy R, Burch M, Kantor PF, et al. Sacubitril\/valsartan in pediatric heart failure (PANORAMA-HF): a randomized, multicenter, double-blind trial. Circulation. 2024;150(22):1756\u201366.","journal-title":"Circulation"},{"issue":"1","key":"739_CR69","doi-asserted-by":"publisher","first-page":"6295345","DOI":"10.1155\/2024\/6295345","volume":"2024","author":"R Dos Santos Borges","year":"2024","unstructured":"Dos Santos Borges R, Conegundes AF, Haikal De Paula L, et al. Efficacy and safety of SGLT2 inhibitors in pediatric patients and young adults: a systematic review and meta-analysis of randomized controlled trials. Pediatr Diabetes. 2024;2024(1):6295345.","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"739_CR70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40272-024-00623-z","volume":"26","author":"SAG Lava","year":"2024","unstructured":"Lava SAG, Laurence C, Di Deo A, et al. Dapagliflozin and empagliflozin in paediatric indications: a systematic review. Paediatr Drugs. 2024;26(3):229\u201343.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"739_CR71","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","volume":"44","author":"DM Newland","year":"2023","unstructured":"Newland DM, Law YM, Albers EL, et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146\u201352.","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"739_CR72","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12887-024-05022-4","volume":"24","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Da M, Yang X, et al. A retrospective analysis of clinical characteristics and outcomes of pediatric fulminant myocarditis. BMC Pediatr. 2024;24(1):553.","journal-title":"BMC Pediatr"},{"issue":"5","key":"739_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jacc.2023.11.019","volume":"83","author":"K Puri","year":"2024","unstructured":"Puri K, Jentzer JC, Spinner JA, et al. Clinical presentation, classification, and outcomes of cardiogenic shock in children. J Am Coll Cardiol. 2024;83(5):595\u2013608.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"739_CR74","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MAT.0000000000001430","volume":"68","author":"SG Al-Kindi","year":"2022","unstructured":"Al-Kindi SG, Xie R, Kirklin JK, et al. Outcomes of durable mechanical circulatory support in myocarditis: analysis of the International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support Registry. ASAIO J. 2022;68(2):190\u20136.","journal-title":"ASAIO J"},{"issue":"3","key":"739_CR75","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ehf2.12629","volume":"7","author":"CFJ Antonides","year":"2020","unstructured":"Antonides CFJ, Schoenrath F, De By TMMH, et al. Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. ESC Heart Fail. 2020;7(3):1085\u201394.","journal-title":"ESC Heart Fail."},{"issue":"22","key":"739_CR76","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.CIR.0000072766.67150.51","volume":"107","author":"U K\u00fcHl","year":"2003","unstructured":"K\u00fcHl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-\u03b2 treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793\u20138.","journal-title":"Circulation"},{"issue":"3","key":"739_CR77","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcv.2010.07.008","volume":"49","author":"PI Rafailidis","year":"2010","unstructured":"Rafailidis PI, Mavros MN, Kapaskelis A, et al. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49(3):151\u20137.","journal-title":"J Clin Virol"},{"key":"739_CR78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.idcr.2018.02.008","volume":"12","author":"LM Saraca","year":"2018","unstructured":"Saraca LM, Lazzari L, di Giuli C, et al. Cytomegalovirus myocarditis in a patient with systemic lupus erythematosus (SLE) successfully treated with ganciclovir. IDCases. 2018;12:4\u20136.","journal-title":"IDCases."},{"issue":"22","key":"739_CR79","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.3390\/jcm10225240","volume":"10","author":"H-P Schultheiss","year":"2021","unstructured":"Schultheiss H-P, Baumeier C, Aleshcheva G, et al. Viral myocarditis: from pathophysiology to treatment. J Clin Med. 2021;10(22):5240.","journal-title":"J Clin Med"},{"issue":"2","key":"739_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/v14020444","volume":"14","author":"H-P Schultheiss","year":"2022","unstructured":"Schultheiss H-P, Bock C-T, Aleshcheva G, et al. Interferon-\u03b2 suppresses transcriptionally active parvovirus B19 infection in viral cardiomyopathy: a subgroup analysis of the BICC-trial. Viruses. 2022;14(2):444.","journal-title":"Viruses"},{"issue":"2","key":"739_CR81","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00392-021-01955-3","volume":"111","author":"T Koenig","year":"2022","unstructured":"Koenig T, Kempf T, Schultheiss H-P, et al. Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. Clin Res Cardiol. 2022;111(2):233\u20136.","journal-title":"Clin Res Cardiol"},{"issue":"19","key":"739_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195519","volume":"11","author":"S Urban","year":"2022","unstructured":"Urban S, Fu\u0142ek M, B\u0142aziak M, et al. COVID-19 related myocarditis in adults: a systematic review of case reports. J Clin Med. 2022;11(19):5519.","journal-title":"J Clin Med"},{"issue":"14","key":"739_CR83","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2012.06.026","volume":"60","author":"U K\u00fchl","year":"2012","unstructured":"K\u00fchl U, Lassner D, Von Schlippenbach J, et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012;60(14):1295\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"739_CR84","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.3389\/ti.2023.11785","volume":"36","author":"CS Walti","year":"2023","unstructured":"Walti CS, Khanna N, Avery RK, et al. New treatment options for refractory\/resistant CMV infection. Transpl Int. 2023;36:11785.","journal-title":"Transpl Int"},{"key":"739_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105842","volume":"224","author":"A Ianevski","year":"2024","unstructured":"Ianevski A, Froysa IT, Lysvand H, et al. The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. Antiviral Res. 2024;224:105842.","journal-title":"Antiviral Res"},{"issue":"12","key":"739_CR86","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","volume":"27","author":"MK Yong","year":"2021","unstructured":"Yong MK, Shigle TL, Kim Y-J, et al. American Society for Transplantation and Cellular Therapy Series: #4\u2014cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(12):957\u201367.","journal-title":"Transplant Cell Ther."},{"issue":"2\u20133","key":"739_CR87","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00430-003-0200-3","volume":"193","author":"A Heim","year":"2004","unstructured":"Heim A, Weiss S. Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol. 2004;193(2\u20133):149\u201354.","journal-title":"Med Microbiol Immunol"},{"issue":"2","key":"739_CR88","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcv.2013.02.005","volume":"57","author":"N Hakacova","year":"2013","unstructured":"Hakacova N, Klingel K, Kandolf R, et al. First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child. J Clin Virol. 2013;57(2):157\u201360.","journal-title":"J Clin Virol"},{"issue":"6","key":"739_CR89","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1086\/591195","volume":"47","author":"T Efferth","year":"2008","unstructured":"Efferth T, Romero MR, Wolf DG, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47(6):804\u201311.","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"739_CR90","doi-asserted-by":"publisher","first-page":"10","DOI":"10.37201\/req\/s03.03.2022","volume":"35","author":"TF Aiello","year":"2022","unstructured":"Aiello TF, Garc\u00eda-Vidal C, Soriano A. Antiviral drugs against SARS-CoV-2. Rev Esp Quimioter. 2022;35(Suppl. 3):10\u20135.","journal-title":"Rev Esp Quimioter"},{"issue":"4","key":"739_CR91","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334\u201346.","journal-title":"N Engl J Med"},{"issue":"16","key":"739_CR92","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","volume":"30","author":"A Frustaci","year":"2009","unstructured":"Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30(16):1995\u20132002.","journal-title":"Eur Heart J"},{"issue":"5","key":"739_CR93","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason JW, O\u2019Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333(5):269\u201375.","journal-title":"N Engl J Med"},{"issue":"14","key":"739_CR94","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.2169\/internalmedicine.2471-18","volume":"58","author":"T Akita","year":"2019","unstructured":"Akita T, Mori S, Onishi A, et al. Successful triple combination immunosuppressive therapy with prednisolone, cyclosporine, and mycophenolate mofetil to treat recurrent giant cell myocarditis. Intern Med. 2019;58(14):2035\u20139.","journal-title":"Intern Med"},{"issue":"8","key":"739_CR95","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jacc.2020.11.074","volume":"77","author":"V Bang","year":"2021","unstructured":"Bang V, Ganatra S, Shah SP, et al. Management of patients with giant cell myocarditis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(8):1122\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"739_CR96","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/tri.12270","volume":"27","author":"G Toscano","year":"2014","unstructured":"Toscano G, Tartaro P, Fedrigo M, et al. Rituximab in recurrent idiopathic giant cell myocarditis after heart transplantation: a potential therapeutic approach. Transpl Int. 2014;27(5):e38-42.","journal-title":"Transpl Int"},{"key":"739_CR97","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytac362","author":"ES Frankel","year":"2022","unstructured":"Frankel ES, Hajduczok AG, Rajapreyar IN, et al. Recurrent giant cell myocarditis after heart transplant: a case report. Eur Heart J Case Rep. 2022. https:\/\/doi.org\/10.1093\/ehjcr\/ytac362.","journal-title":"Eur Heart J Case Rep"},{"issue":"11","key":"739_CR98","doi-asserted-by":"publisher","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","volume":"13","author":"E Ammirati","year":"2020","unstructured":"Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy. Circ Heart Fail. 2020;13(11):e007405.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"739_CR99","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.healun.2015.10.009","volume":"35","author":"JD Evans","year":"2016","unstructured":"Evans JD, Pettit SJ, Goddard M, et al. Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation. J Heart Lung Transplant. 2016;35(2):256\u20138.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"739_CR100","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1053-2498(00)00314-4","volume":"20","author":"RL Scott","year":"2001","unstructured":"Scott RL, Ratliff NB, Starling RC, et al. Recurrence of giant cell myocarditis in cardiac allograft. J Heart Lung Transplant. 2001;20(3):375\u201380.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"739_CR101","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/ejhf.3220","volume":"26","author":"ALP Caforio","year":"2024","unstructured":"Caforio ALP, Giordani AS, Baritussio A, et al. Long-term efficacy and safety of tailored immunosuppressive therapy in immune-mediated biopsy-proven myocarditis: a propensity-weighted study. Eur J Heart Fail. 2024;26(5):1175\u201385.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"739_CR102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004228","volume":"11","author":"J Merken","year":"2018","unstructured":"Merken J, Hazebroek M, Van Paassen P, et al. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail. 2018;11(2):e004228.","journal-title":"Circ Heart Fail"},{"key":"739_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2020.04.050","volume":"77","author":"G De Luca","year":"2020","unstructured":"De Luca G, Campochiaro C, Sartorelli S, et al. Therapeutic strategies for virus-negative myocarditis: a comprehensive review. Eur J Intern Med. 2020;77:9\u201317.","journal-title":"Eur J Intern Med"},{"key":"739_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.838564","author":"E Ammirati","year":"2022","unstructured":"Ammirati E, Bizzi E, Veronese G, et al. Immunomodulating therapies in acute myocarditis and recurrent\/acute pericarditis. Front Med. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.838564.","journal-title":"Front Med"},{"issue":"11","key":"739_CR105","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","volume":"102","author":"LT Cooper","year":"2008","unstructured":"Cooper LT, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102(11):1535\u20139.","journal-title":"Am J Cardiol"},{"issue":"6","key":"739_CR106","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1017\/S1047951121004327","volume":"32","author":"G Lourenco","year":"2022","unstructured":"Lourenco G, Pimentel J, Trigo C, et al. Paediatric giant cell myocarditis: a case report. Cardiol Young. 2022;32(6):1010\u20132.","journal-title":"Cardiol Young"},{"issue":"2","key":"739_CR107","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00246-022-03004-w","volume":"44","author":"J Schauer","year":"2023","unstructured":"Schauer J, Newland D, Hong B, et al. Treating pediatric myocarditis with high dose steroids and immunoglobulin. Pediatr Cardiol. 2023;44(2):441\u201350.","journal-title":"Pediatr Cardiol"},{"issue":"5","key":"739_CR108","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1017\/S1047951110000594","volume":"20","author":"KU Aziz","year":"2010","unstructured":"Aziz KU, Patel N, Sadullah T, et al. Acute viral myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young. 2010;20(5):509\u201315.","journal-title":"Cardiol Young"},{"key":"739_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01423-w","author":"Q Yao","year":"2023","unstructured":"Yao Q, Zhan S. Corticosteroid in anti-inflammatory treatment of pediatric acute myocarditis: a systematic review and meta-analysis. Ital J Pediatr. 2023. https:\/\/doi.org\/10.1186\/s13052-023-01423-w.","journal-title":"Ital J Pediatr"},{"key":"739_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00342","author":"Y Li","year":"2019","unstructured":"Li Y, Yu Y, Chen S, et al. Corticosteroids and intravenous immunoglobulin in pediatric myocarditis: a meta-analysis. Front Pediatr. 2019. https:\/\/doi.org\/10.3389\/fped.2019.00342.","journal-title":"Front Pediatr"},{"issue":"10","key":"739_CR111","first-page":"CD004471","volume":"2013","author":"HS Chen","year":"2013","unstructured":"Chen HS, Wang W, Wu SN, et al. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2013;2013(10):CD004471.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"739_CR112","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jaip.2023.04.002","volume":"11","author":"J Bayry","year":"2023","unstructured":"Bayry J, Ahmed EA, Toscano-Rivero D, et al. Intravenous immunoglobulin: mechanism of action in autoimmune and inflammatory conditions. J Allergy Clin Immunol Pract. 2023;11(6):1688\u201397.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"739_CR113","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00246-012-0350-4","volume":"33","author":"GC Bhatt","year":"2012","unstructured":"Bhatt GC, Sankar J, Kushwaha KP. Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol. 2012;33(8):1370\u20136.","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"739_CR114","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/S1047951117001561","volume":"28","author":"JF Heidendael","year":"2018","unstructured":"Heidendael JF, Den Boer SL, Wildenbeest JG, et al. Intravenous immunoglobulins in children with new onset dilated cardiomyopathy. Cardiol Young. 2018;28(1):46\u201354.","journal-title":"Cardiol Young"},{"issue":"11","key":"739_CR115","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1253\/circj.CJ-16-0234","volume":"80","author":"H Matsuura","year":"2016","unstructured":"Matsuura H, Ichida F, Saji T, et al. Clinical features of acute and fulminant myocarditis in children: 2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. Circ J. 2016;80(11):2362\u20138.","journal-title":"Circ J"},{"key":"739_CR116","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jcv.2015.01.013","volume":"64","author":"MH Yen","year":"2015","unstructured":"Yen MH, Huang YC, Chen MC, et al. Effect of intravenous immunoglobulin for neonates with severe enteroviral infections with emphasis on the timing of administration. J Clin Virol. 2015;64:92\u20136.","journal-title":"J Clin Virol"},{"issue":"7","key":"739_CR117","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s13312-014-0456-2","volume":"51","author":"AN Prasad","year":"2014","unstructured":"Prasad AN, Chaudhary S. Intravenous immunoglobulin in children with acute myocarditis and\/or early dilated cardiomyopathy. Indian Pediatr. 2014;51(7):583\u20134.","journal-title":"Indian Pediatr"},{"issue":"2","key":"739_CR118","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00246-009-9589-9","volume":"31","author":"D Klugman","year":"2010","unstructured":"Klugman D, Berger JT, Sable CA, et al. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol. 2010;31(2):222\u20138.","journal-title":"Pediatr Cardiol"},{"issue":"7","key":"739_CR119","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3345\/kjp.2010.53.7.745","volume":"53","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Yoo G-H, Kil HR. Clinical outcome of acute myocarditis in children according to treatment modalities. Korean J Pediatr. 2010;53(7):745.","journal-title":"Korean J Pediatr"},{"issue":"9","key":"739_CR120","first-page":"810","volume":"46","author":"A Haque","year":"2009","unstructured":"Haque A, Bhatti S, Siddiqui FJ. Intravenous immune globulin for severe acute myocarditis in children. Indian Pediatr. 2009;46(9):810\u20131.","journal-title":"Indian Pediatr"},{"issue":"5","key":"739_CR121","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/S1047951104005049","volume":"14","author":"RF English","year":"2004","unstructured":"English RF, Janosky JE, Ettedgui JA, et al. Outcomes for children with acute myocarditis. Cardiol Young. 2004;14(5):488\u201393.","journal-title":"Cardiol Young"},{"issue":"1","key":"739_CR122","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1161\/01.CIR.89.1.252","volume":"89","author":"NA Drucker","year":"1994","unstructured":"Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252\u20137.","journal-title":"Circulation"},{"issue":"11","key":"739_CR123","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1161\/01.CIR.95.11.2476","volume":"95","author":"DM McNamara","year":"1997","unstructured":"McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation. 1997;95(11):2476\u20138.","journal-title":"Circulation"},{"issue":"5","key":"739_CR124","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1253\/circj.CJ-11-1032","volume":"76","author":"T Saji","year":"2012","unstructured":"Saji T, Matsuura H, Hasegawa K, et al. Comparison of the clinical presentation, treatment, and outcome of fulminant and acute myocarditis in children. Circ J. 2012;76(5):1222\u20138.","journal-title":"Circ J"},{"key":"739_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101389","author":"SA El-Saiedi","year":"2023","unstructured":"El-Saiedi SA, Fathalla A, Gaber H, et al. New strategies in the treatment of advanced heart failure in children and the current consensus of Cairo University Children Hospital Heart Failure Working Group. Curr Probl Cardiol. 2023. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101389.","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"739_CR126","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1536\/ihj.18-299","volume":"60","author":"X Huang","year":"2019","unstructured":"Huang X, Sun Y, Su G, et al. Intravenous immunoglobulin therapy for acute myocarditis in children and adults. Int Heart J. 2019;60(2):359\u201365.","journal-title":"Int Heart J"},{"issue":"8","key":"739_CR127","first-page":"CD004370","volume":"8","author":"J Robinson","year":"2020","unstructured":"Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020;8(8):CD004370.","journal-title":"Cochrane Database Syst Rev"},{"key":"739_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.09.054","volume":"273","author":"R Mei","year":"2018","unstructured":"Mei R, Raschi E, Forcesi E, et al. Myocarditis and pericarditis after immunization: gaining insights through the Vaccine Adverse Event Reporting System. Int J Cardiol. 2018;273:183\u20136.","journal-title":"Int J Cardiol"},{"issue":"4","key":"739_CR129","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2022","unstructured":"Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331\u201340.","journal-title":"JAMA"},{"issue":"5","key":"739_CR130","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/CIRCULATIONAHA.121.056583","volume":"145","author":"DT Truong","year":"2022","unstructured":"Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345\u201356.","journal-title":"Circulation"},{"issue":"6","key":"739_CR131","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.18505","volume":"5","author":"SA Buchan","year":"2022","unstructured":"Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022;5(6):e2218505.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"739_CR132","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa1215","volume":"72","author":"PM Lantos","year":"2021","unstructured":"Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021;72(1):e1-48.","journal-title":"Clin Infect Dis"},{"issue":"18","key":"739_CR133","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","volume":"298","author":"C Bern","year":"2007","unstructured":"Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States. JAMA. 2007;298(18):2171\u201381.","journal-title":"JAMA"},{"key":"739_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092565","author":"S Kann","year":"2024","unstructured":"Kann S, Concha G, Frickmann H, et al. Chagas disease: comparison of therapy with nifurtimox and benznidazole in indigenous communities in Colombia. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13092565.","journal-title":"J Clin Med"},{"key":"739_CR135","first-page":"53","volume":"29","author":"N Nathan","year":"2019","unstructured":"Nathan N, Sileo C, Calender A, et al. Paediatric sarcoidosis. Paediatr Respir Rev. 2019;29:53\u20139.","journal-title":"Paediatr Respir Rev"},{"key":"739_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072097","author":"S Chauveau","year":"2020","unstructured":"Chauveau S, Jeny F, Montagne ME, et al. Child-adult transition in sarcoidosis: a series of 52 patients. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9072097.","journal-title":"J Clin Med"},{"issue":"21","key":"739_CR137","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","volume":"149","author":"RK Cheng","year":"2024","unstructured":"Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation. 2024;149(21):e1197\u2013216.","journal-title":"Circulation"},{"issue":"10","key":"739_CR138","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","volume":"10","author":"DL Nielsen","year":"2024","unstructured":"Nielsen DL, Juhl CB, Nielsen OH, et al. Immune checkpoint inhibitor-induced cardiotoxicity. JAMA Oncol. 2024;10(10):1390\u20139.","journal-title":"JAMA Oncol"},{"key":"739_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcped.2023.100117","volume":"2","author":"M Cupit-Link","year":"2023","unstructured":"Cupit-Link M, Khan R, Pappo A, et al. Immune-related adverse events from immune checkpoint inhibitors in pediatric patients: a literature review and case series. EJC Paediatr Oncol. 2023;2:100117.","journal-title":"EJC Paediatr Oncol."},{"key":"739_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275254","author":"C Wang","year":"2023","unstructured":"Wang C, Zhao G, Zhang Z, et al. Immune checkpoint inhibitor\u2013associated myocarditis: a systematic analysis of case reports. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1275254.","journal-title":"Front Immunol"},{"issue":"1","key":"739_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-025-02232-9","volume":"27","author":"AM Hachem","year":"2025","unstructured":"Hachem AM, Desai A, Beinart N, et al. Updates in diagnosis and treatment of immune checkpoint inhibitor myocarditis. Curr Cardiol Rep. 2025;27(1):78.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"739_CR142","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/eurheartj\/ehy730","volume":"40","author":"A Pelliccia","year":"2019","unstructured":"Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2019;40(1):19\u201333.","journal-title":"Eur Heart J"},{"key":"739_CR143","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004262","author":"J Berg","year":"2017","unstructured":"Berg J, Kottwitz J, Baltensperger N, et al. Cardiac magnetic resonance imaging in myocarditis reveals persistent disease activity despite normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up. Circ Heart Fail. 2017. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004262.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"739_CR144","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.123.004487","volume":"17","author":"W Huang","year":"2024","unstructured":"Huang W, Yin C, Lento PA, et al. Differential deep RNA sequencing for diagnostic detection of microbial infections in inflammatory cardiomyopathy. Circ Genom Precis Med. 2024;17(4):e004487.","journal-title":"Circ Genom Precis Med"},{"key":"739_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115845","author":"C Baumeier","year":"2024","unstructured":"Baumeier C, Harms D, Altmann B, et al. Epstein-Barr virus lytic transcripts correlate with the degree of myocardial inflammation in heart failure patients. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115845.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"739_CR146","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"739_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020212","volume":"9","author":"J Iking","year":"2021","unstructured":"Iking J, Staniszewska M, Kessler L, et al. Imaging inflammation with positron emission tomography. Biomedicines. 2021;9(2):212.","journal-title":"Biomedicines"},{"issue":"1","key":"739_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210971","volume":"14","author":"K Noguchi","year":"2019","unstructured":"Noguchi K, Tomita H, Kanayama T, et al. Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation. PLoS ONE. 2019;14(1):e0210971.","journal-title":"PLoS ONE"},{"issue":"9","key":"739_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091277","volume":"10","author":"A Hara","year":"2020","unstructured":"Hara A, Niwa M, Kanayama T, et al. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 2020;10(9):1277.","journal-title":"Biomolecules"},{"issue":"12","key":"739_CR150","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/ejhf.579","volume":"18","author":"C Besler","year":"2016","unstructured":"Besler C, Urban D, Watzka S, et al. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail. 2016;18(12):1442\u201351.","journal-title":"Eur J Heart Fail"},{"key":"739_CR151","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024417","author":"J Wang","year":"2022","unstructured":"Wang J, He M, Li H, et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis. J Am Heart Assoc. 2022. https:\/\/doi.org\/10.1161\/JAHA.121.024417.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"739_CR152","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","volume":"9","author":"JF Merola","year":"2022","unstructured":"Merola JF, McInnes IB, Deodhar AA, et al. Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther. 2022;9(3):935\u201355.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"739_CR153","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvab015","volume":"118","author":"M Mirna","year":"2022","unstructured":"Mirna M, Paar V, Topf A, et al. A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis. Cardiovasc Res. 2022;118(2):556\u201372.","journal-title":"Cardiovasc Res"},{"issue":"16","key":"739_CR154","first-page":"7144","volume":"23","author":"CL Li","year":"2019","unstructured":"Li CL, Jia LB, Gao J, et al. The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis. Eur Rev Med Pharmacol Sci. 2019;23(16):7144\u201351.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"Suppl._1","key":"739_CR155","doi-asserted-by":"publisher","first-page":"ehae666.1239","DOI":"10.1093\/eurheartj\/ehae666.1239","volume":"45","author":"E Ammirati","year":"2024","unstructured":"Ammirati E, Conti N, Frea S, et al. Rationale and study design of the international randomized control trial MYocarditis THerapy with Steroids: the MYTHS trial. Eur Heart J. 2024;45(Suppl._1):ehae666.1239.","journal-title":"Eur Heart J"},{"issue":"2","key":"739_CR156","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, et al. Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315.","journal-title":"Arch Cardiovasc Dis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00739-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00739-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00739-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:02:44Z","timestamp":1777291364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00739-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00739-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bibhuti Das has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"BD conceptualized, wrote, and edited this article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}